GEORGE R BLUMENSCHEIN to Pyridones
This is a "connection" page, showing publications GEORGE R BLUMENSCHEIN has written about Pyridones.
Connection Strength
0.431
-
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)?. Ann Oncol. 2015 May; 26(5):894-901.
Score: 0.403
-
A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced?Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 03; 12(3):556-566.
Score: 0.028